A novel long-term prediction model showed promise at estimating the risk for dying of prostate cancer, an analysis published ...

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...

Life-extending prostate cancer drug to be made available to thousands more patients - Men with high-risk prostate cancer that ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

Research from the University of Cambridge may be able to start a national screening programme for the common cancer ...

Abiraterone will be available in a matter of weeks and will be offered to 7,000 men a year.

NHS England has announced that men whose high-risk prostate cancer has not yet spread will be able to receive the drug, ...

Mr. Green, a 50-something businessman was asking a question I find myself answering on a surprisingly regular basis: “So, my PSA went up; what does that mean?” ...